n Cardiovascular Journal of South Africa - Rosuvastatin receives FDA approval : drug trends in cardiology
|Article Title||Rosuvastatin receives FDA approval : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of South Africa|
|Publication Date||Sep 2003|
Extracted from text ... 286 AstraZeneca has announced that its new cholesterol-lowering medication, rosuvastatin calcium, which has been shown to lower LDL cholesterol by up to 63%, has received approval from the US Food and Drug Administration (FDA) as an adjunct to diet for the treatment of various lipid disorders, including primary hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia. This follows the successful advisory committee meeting held in the US in July 2003, where the committee voted unanimously to recommend the approval of rosuvastatin. Rosuvastatin is the newest member of the cholesterol-lowering statin class (HMG-CoA reductase inhibitors) of drug therapy. In addition to its LDL (low-density ..
Article metrics loading...